Shenzhen Mindray Bio Medical Stock Current Valuation
| 300760 Stock | 255.28 0.78 0.31% |
Valuation analysis of Shenzhen Mindray Bio helps investors to measure Shenzhen Mindray's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of February 26, 2025, Cash is expected to decline to about 13.5 B. The current year's Change In Cash is expected to grow to about (261 M). Fundamental drivers impacting Shenzhen Mindray's valuation include:
Price Book 8.3185 | Enterprise Value 291.2 B | Enterprise Value Ebitda 20.9802 | Price Sales 8.262 | Forward PE 21.0084 |
Fairly Valued
Today
Please note that Shenzhen Mindray's price fluctuation is very steady at this time. Calculation of the real value of Shenzhen Mindray Bio is based on 3 months time horizon. Increasing Shenzhen Mindray's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Shenzhen Mindray is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Shenzhen Stock. However, Shenzhen Mindray's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 255.28 | Real 251.93 | Hype 254.55 | Naive 248.82 |
The real value of Shenzhen Stock, also known as its intrinsic value, is the underlying worth of Shenzhen Mindray Bio Company, which is reflected in its stock price. It is based on Shenzhen Mindray's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Shenzhen Mindray's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Shenzhen Mindray Bio Medical helps investors to forecast how Shenzhen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Shenzhen Mindray more accurately as focusing exclusively on Shenzhen Mindray's fundamentals will not take into account other important factors: Shenzhen Mindray Bio Medical Company Current Valuation Analysis
Shenzhen Mindray's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Shenzhen Mindray Current Valuation | 291.21 B |
Most of Shenzhen Mindray's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shenzhen Mindray Bio Medical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Shenzhen Mindray Bio Medical has a Current Valuation of 291.21 B. This is much higher than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The current valuation for all China stocks is significantly lower than that of the firm.
Shenzhen Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shenzhen Mindray's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Shenzhen Mindray could also be used in its relative valuation, which is a method of valuing Shenzhen Mindray by comparing valuation metrics of similar companies.Shenzhen Mindray is currently under evaluation in current valuation category among its peers.
Shenzhen Fundamentals
| Return On Equity | 0.32 | ||||
| Return On Asset | 0.16 | ||||
| Profit Margin | 0.33 % | ||||
| Operating Margin | 0.43 % | ||||
| Current Valuation | 291.21 B | ||||
| Shares Outstanding | 1.21 B | ||||
| Shares Owned By Insiders | 57.41 % | ||||
| Shares Owned By Institutions | 19.01 % | ||||
| Price To Book | 8.32 X | ||||
| Price To Sales | 8.26 X | ||||
| Revenue | 34.93 B | ||||
| Gross Profit | 24.47 B | ||||
| EBITDA | 14.41 B | ||||
| Net Income | 11.58 B | ||||
| Total Debt | 7.75 M | ||||
| Book Value Per Share | 30.59 X | ||||
| Cash Flow From Operations | 11.06 B | ||||
| Earnings Per Share | 10.21 X | ||||
| Target Price | 345.41 | ||||
| Number Of Employees | 18.04 K | ||||
| Beta | 0.23 | ||||
| Market Capitalization | 306.63 B | ||||
| Total Asset | 47.94 B | ||||
| Retained Earnings | 24.68 B | ||||
| Working Capital | 16.77 B | ||||
| Annual Yield | 0.05 % | ||||
| Net Asset | 47.94 B | ||||
| Last Dividend Paid | 7.21 |
About Shenzhen Mindray Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shenzhen Mindray Bio Medical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shenzhen Mindray using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shenzhen Mindray Bio Medical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Shenzhen Stock
Shenzhen Mindray financial ratios help investors to determine whether Shenzhen Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shenzhen with respect to the benefits of owning Shenzhen Mindray security.